X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain
about
Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptorDeciphering Modern Glucocorticoid Cross-pharmacology Using Ancestral Corticosteroid ReceptorsStructures and mechanism for the design of highly potent glucocorticoidsOrg 214007-0: a novel non-steroidal selective glucocorticoid receptor modulator with full anti-inflammatory properties and improved therapeutic indexStructure of a 13-fold superhelix (almost) determined from first principles.Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.The significance of chirality in drug design and development.Investigation on critical structural motifs of ligands for triggering glucocorticoid receptor nuclear migration through molecular docking simulations.Hormone binding and co-regulator binding to the glucocorticoid receptor are allosterically coupled.Insights on glucocorticoid receptor activity modulation through the binding of rigid steroids.Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study.The role of the CCR1 receptor in the inflammatory response to tobacco smoke in a mouse modelOnce-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial.Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trialFluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthmaDiscovery of a highly potent glucocorticoid for asthma treatmentAlternate glucocorticoid receptor ligand binding structures influence outcomes in an in vivo tissue regeneration modelUnderstanding nuclear receptor form and function using structural biologyOnce-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPDOnce-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.Structure of the glucocorticoid receptor, a flexible protein that can adapt to different ligands.Rational structure-based drug design and optimization in the ligand-binding domain of the glucocorticoid receptor-α.Rational ligand-based virtual screening and structure-activity relationship studies in the ligand-binding domain of the glucocorticoid receptor-α.A review of the use of fluticasone furoate since its launch.Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.Fluticasone furoate/vilanterol: a review of its use in patients with asthma.Fixed-Dose combination of the inhaled corticosteroid and long-acting beta2-agonist therapy in adults with persistent asthma.Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.Discovery of GW870086: a potent anti-inflammatory steroid with a unique pharmacological profileAn analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics.Crystalline forms of 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)-2-propanyl]acetamide (AZD-5423).A novel mutation of the hGR gene causing Chrousos syndrome.Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
P2860
Q27657764-2594F308-29C8-4EBF-9AA1-0F59449D6AC0Q27678139-186145AA-807B-41ED-8CF7-C1686BB92A1BQ27683537-73DA7C48-3966-47D6-81E1-B89C24B30C84Q28485149-7296C7A1-AE15-4FDE-BCC3-A2FD5008CA4AQ30152952-32BF16CF-5E1D-48EF-8193-1FAEF35E2503Q30418832-F5FD3D81-7078-4DD7-8BF1-2E402423AAEDQ30997748-670D0A62-CEEE-4278-BDA5-84D519745600Q33361175-00590AE0-80FD-41CB-8E4F-330265F3C546Q33545556-22EEB052-C128-46A0-8E4F-CFCEB896A427Q33719222-9AA85E1E-B9A1-4A5D-BA58-58C1495F85ADQ33937441-BAA78FDA-AD7E-4725-A067-7FD6A11EE4A9Q34106030-A25F8EB9-4505-491D-9B64-7DF8D2E286F6Q35086014-252B4AC5-D072-4E5C-AE44-EECF34DBFC82Q35554841-F18374A1-5F52-4BD5-92CA-494387CAFBCFQ35766467-E2C1D0BD-3E03-4FC5-8A71-78A8017F8467Q36769629-C987DC66-903C-48F6-ACCF-3CC5BD9CAAD4Q37134776-AAE3EE5D-C837-47A9-A07A-A7917B6EB615Q37411882-30E429F8-2B8F-444B-8BFC-7F6E4ADCE3D8Q37610412-F405343E-A124-4788-9684-281534F8C941Q37614090-3FCBB640-C50F-497B-B831-9A6D320159F1Q37658668-50EB1D51-165C-437C-A8BF-B24CBB547EFAQ37718094-B04D4D93-D8DD-4C3E-9489-84E39C21D156Q37855809-E1379771-5C45-48B4-A0C1-4CACC1A541A9Q37855890-6C385D0A-4C08-471C-B4C5-F8A952274D9AQ37907340-D7374251-2539-40A9-A4EA-76E94154BACAQ38235191-EDCD3C5B-B500-4827-B804-75B1DF409373Q38342870-C6A58AEB-80EF-4E9A-ADF5-580F85ED5B24Q38707759-93526107-0630-4497-91A5-4237F3CB0A35Q38947467-65CE3D47-8605-4310-AC26-AE566822DBE5Q39157135-DA9D22F3-97D3-4DEA-977C-342243080102Q42073494-AC5D4679-C9A6-49A6-9D64-79BF83362BA2Q44358992-931AFBC2-016B-4E1B-8E0C-9684907369A4Q47691379-FADEA0A6-5B7F-489A-ADC2-11AAA370B3D5Q55057134-B73E6611-705A-4962-B690-9152E00188DE
P2860
X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
X-ray crystal structure of the ...... receptor-ligand binding domain
@ast
X-ray crystal structure of the ...... receptor-ligand binding domain
@en
X-ray crystal structure of the ...... receptor-ligand binding domain
@nl
type
label
X-ray crystal structure of the ...... receptor-ligand binding domain
@ast
X-ray crystal structure of the ...... receptor-ligand binding domain
@en
X-ray crystal structure of the ...... receptor-ligand binding domain
@nl
prefLabel
X-ray crystal structure of the ...... receptor-ligand binding domain
@ast
X-ray crystal structure of the ...... receptor-ligand binding domain
@en
X-ray crystal structure of the ...... receptor-ligand binding domain
@nl
P2093
P921
P356
P1476
X-ray crystal structure of the ...... receptor-ligand binding domain
@en
P2093
Anne M Hassell
Barrie E Kirk
Eugene L Stewart
Iain M McLay
Keith Biggadike
Lisa M Shewchuk
Randy K Bledsoe
P304
P356
10.1021/JM800279T
P407
P577
2008-06-26T00:00:00Z